Regulatory risk Growing compliance and SEC-related scrutiny history indicates a need for robust governance, verifiable claims, and transparent reporting services to ensure regulatory alignment and investor confidence.

Fraud mitigation Past allegations around fraud and kickbacks suggest a market need for independent quality assurance, third-party auditing, and compliance-focused technologies to restore credibility with investors, partners, and customers.

Small-scale ops With a very lean team and revenue under one million, there is an opportunity to offer scalable R&D, contract manufacturing, and automation solutions to accelerate growth without large internal headcount.

Validation services Historical claims about testing technologies create demand for credible validation, clinical study support, and regulatory-grade documentation to differentiate offerings and enable sales to larger CROs and biotech buyers.

Strategic partnerships The company serves diverse life science segments; partnering with contract research organizations, diagnostic firms, or academic labs could expand market access and provide bundled solutions leveraging existing tech stack.